MedTrace Logo

Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.

NCT02602249 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-09-05

No results posted yet for this study

Summary

In this study, safety and effects of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL on human gastric cancer are going to be investigated.

Conditions

Interventions

BIOLOGICAL

MUC1-gene-DC-CTL

MUC1-gene-DC-CTL will be used against tumor cells.

BIOLOGICAL

MUC1-peptide-DC-CTL

MUC1-peptide-DC-CTL will be used against tumor cells.

Sponsors & Collaborators

  • Beijing Doing Biomedical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • li gangyi, master · Beijing Doing Biomedical Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-31
Primary Completion
2019-04-30
Completion
2020-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02602249 on ClinicalTrials.gov